參考文獻 |
[1] 衛生福利部. 2014年死因統計結果. 2015.
[2] Hanahan D, Weinberg RA. The hallmarks of cancer cell. 2000;100:57-70.
[3] Chang K-J, Kuo W-H, Wang M-Y. The epidemiology of breast cancer in Taiwan. J Chinese Oncol Soc. 2008;24:85-93.
[4] Feynman RP. There′s plenty of room at the bottom. Engineering and science. 1960;23:22-36.
[5] 林建中. 奈米科技: 基礎與實務: 新文京開發; 2006.
[6] 馬遠榮. 奈米科技: 商周出版; 2002.
[7] Freitas RA. What is nanomedicine? Nanomedicine: Nanotechnology, Biology and Medicine. 2005;1:2-9.
[8] Sudeep P, Joseph SS, Thomas KG. Selective detection of cysteine and glutathione using gold nanorods.Journal of the American Chemical Society. 2005;127:6516-7.
[9] Lin Y-S, Wu S-H, Hung Y, Chou Y-H, Chang C, Lin M-L, et al. Multifunctional composite nanoparticles: magnetic, luminescent, and mesoporous. Chemistry of Materials. 2006;18:5170-2.
[10] 張芳瑜. 磁共振造影及光熱治療之雙功能複合材料: 二氧化矽/氧化鐵/金奈米管與 Gd2O (CO3) 2‧ H2O/二氧化矽/金複合粒子的製備與探討. 成功大學化學系學位論文. 2008:1-90.
[11] Cheng F-Y, Wang SP-H, Su C-H, Tsai T-L, Wu P-C, Shieh D-B, et al. Stabilizer-free poly (lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials. 2008;29:2104-12.
[12] Ma J, Jemal A. Breast cancer statistics. Breast Cancer Metastasis and Drug Resistance: Springer; 2013. p. 1-18.
[13] 國家衛生研究院. 乳癌診斷與治療共識. 2004.
[14] Unit EI. breast cancer in asia. 2016.
[15] 和信致癌中心. 女人與癌症. 天下生活股份有限公司; 2000.
[16] 李雅萱. 以巨噬細胞承載包覆藥物相變液滴作為藥物傳遞載體之可行性研究. 清華大學生醫工程與環境科學系學位論文. 2012:1-83.
[17] 吳德維. 高溫腫瘤治療用超音波換能器分析. 台南市: 崑山科技大學; 2006.
[18] 張金堅, Zhang J. 乳房醫學: 健康世界雜誌社; 1993.
[19] 康森防癌健康網. 癌症的治療. 2016.
[20] Kusumaningrum S, Budianto E, Kosela S, Sumaryono W, Juniarti F. The molecular docking of 1, 4-naphthoquinone derivatives as inhibitors of polo-like kinase 1 using Molegro Virtual Docker. J App Sci. 2014;4:47-53.
[21] 維基百科. 阿黴素. 2016.
[22] Rossi S. Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3; 2013.
[23] Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin‐DNA adducts. IUBMB life. 2005;57:73-81.
[24] Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic acids research. 2008;36:e100-e.
[25] Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical pharmacology. 1999;57:727-41.
[26] Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences. 2008;105:9053-8.
[27] Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2011;21:440.
[28] Khouri MG, Hornsby WE, Risum N, Velazquez EJ, Thomas S, Lane A, et al. Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast cancer research and treatment. 2014;143:531-9.
[29] KERR DJ. Microparticulate drug delivery systems as an adjunct to cancer treatment.Cancer drug delivery. 1987;4:55-61.
[30] Meng H, Xue M, Xia T, Ji Z, Tarn DY, Zink JI, et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS NANO. 2011;5:4131-44.
[31] Elbialy NS, Mady MM. Ehrlich tumor inhibition using doxorubicin containing liposomes. Saudi Pharmaceutical Journal. 2015;23:182-7.
[32] Tinkov S, Coester C, Serba S, Geis NA, Katus HA, Winter G, et al. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization. Journal of Controlled Release. 2010;148:368-72.
[33] Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. Journal of Clinical Oncology. 1995;13:1777-85.
[34] Ranson MR, Carmichael J, O′Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. Journal of Clinical Oncology. 1997;15:3185-91.
[35] Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta. 2014;1845:84-9.
[36] Hegyi G, Szigeti GP, Szász A. Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evidence-Based Complementary and Alternative Medicine. 2013;2013.
[37] Falk M, Issels R. Hyperthermia in oncology. International Journal of Hyperthermia. 2001;17:1-18.
[38] Srinivasan S, Manchanda R, Lei T, Nagesetti A, Fernandez-Fernandez A, McGoron AJ. Targeted nanoparticles for simultaneous delivery of chemotherapeutic and hyperthermia agents--an in vitro study. J Photochem Photobiol B. 2014;136:81-90.
[39] Tang Y, McGoron AJ. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B. 2009;97:138-44.
[40] Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. The lancet oncology. 2002;3:487-97.
[41] Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia.Surgical oncology. 1998;7:83-90.
[42] Fessenden P, Hand JW. Hyperthermia therapy physics. Radiation Therapy Physics: Springer; 1995. p. 315-63.
[43] Behrouzkia Z, Joveini Z, Keshavarzi B, Eyvazzadeh N, Aghdam RZ. Hyperthermia: How Can It Be Used? Oman Med J. 2016;31:89-97.
[44] Dewey W, Hopwood L, Sapareto S, Gerweck L. Cellular Responses to Combinations of Hyperthermia and Radiation 1. Radiology. 1977;123:463-74.
[45] van der Zee J. Heating the patient: a promising approach? Annals of oncology. 2002;13:1173-84.
[46] Matylevitch NP, Schuschereba ST, Mata JR, Gilligan GR, Lawlor DF, Goodwin CW, et al. Apoptosis and accidental cell death in cultured human keratinocytes after thermal injury. The American journal of pathology. 1998;153:567-77.
[47] Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-57.
[48] Weissleder R. A clearer vision for in vivo imaging.Nature biotechnology. 2001;19:316-7.
[49] Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1:325-7.
[50] Diagaradjane P, Shetty A, Wang JC, Elliott AM, Schwartz J, Shentu S, et al. Modulation of in vivo tumor radiation response via gold nanoshell-mediated vascular-focused hyperthermia: characterizing an integrated antihypoxic and localized vascular disrupting targeting strategy. Nano letters. 2008;8:1492-500.
[51] Hirsch L, Stafford R, Bankson J, Sershen S, Rivera B, Price R, et al. Ultrafast electron relaxation via breathing vibration of gold nanocrystals embedded in a dielectric medium. PNAS. 2003;100:13549-54.
[52] Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. Journal of the National Cancer Institute. 1998;90:889-905.
[53] Bedwell J, MacRobert A, Phillips D, Bown S. Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model. British journal of cancer. 1992;65:818.
[54] Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer. Drugs. 1999;57:725-34.
[55] Nisnevitch M, Nakonechny F, Nitzan Y. Photodynamic antimicrobial chemotherapy by liposome-encapsulated water-soluble photosensitizers. Russian Journal of Bioorganic Chemistry. 2010;36:363-9.
[56] Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nature reviews cancer. 2003;3:380-7.
[57] Webber J, Herman M, Kessel D, Fromm D. Current concepts in gastrointestinal photodynamic therapy. Annals of surgery. 1999;230:12.
[58] Puolakkainen P, Rämö J, Schröder T. Review: Photodynamic Therapy in Gastroenterology. Scandinavian journal of gastroenterology. 1990;25:417-21.
[59] Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. Journal of the American Academy of Dermatology. 2000;42:389-413.
[60] Kubba A. Role of photodynamic therapy in the management of gastrointestinal cancer. Digestion. 1999;60:1-10.
[61] Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6:535-45.
[62] Yu J, Yaseen MA, Anvari B, Wong MS. Synthesis of near-infrared-absorbing nanoparticle-assembled capsules. Chemistry of Materials. 2007;19:1277-84.
[63] JM D, Soulié S, Mordon S, Desmettre T, Maillols H. Fluorescence properties of indocyanin green-part 1.: in-vitro study with micelles and liposomes.
[64] Miwa M. The principle of ICG fluorescence method. Open Surg Oncol J. 2010;2:26-8.
[65] Bennett TJ, Barry CJ. Ophthalmic imaging today: an ophthalmic photographer′s viewpoint–a review. Clinical & experimental ophthalmology. 2009;37:2-13.
[66] Inaging GR. Indocyanine green optical properties. 2016.
[67] Han L, Zhang Y, Chen X-W, Shu Y, Wang J-H. Protein-modified hollow copper sulfide nanoparticles carrying indocyanine green for photothermal and photodynamic therapy. Journal of Materials Chemistry B. 2016;4:105-12.
[68] Wang YG, Kim H, Mun S, Kim D, Choi Y. Indocyanine green-loaded perfluorocarbon nanoemulsions for bimodal (19)F-magnetic resonance/nearinfrared fluorescence imaging and subsequent phototherapy. Quant Imaging Med Surg. 2013;3:132-40.
[69] Zhou JF, Chin MP, Schafer SA. Aggregation and degradation of indocyanine green. OE/LASE′94: International Society for Optics and Photonics; 1994. p. 495-505.
[70] Landsman M, Kwant G, Mook G, Zijlstra W. Light-absorbing properties, stability, and spectral stabilization of indocyanine green. Journal of applied physiology. 1976;40:575-83.
[71] Mordon S, Devoisselle JM, Soulie-Begu S, Desmettre T. Indocyanine green: physicochemical factors affecting its fluorescencein vivo. Microvascular research. 1998;55:146-52.
[72] van den Biesen PR, Jongsma FH, Tangelder GJ, Slaaf DW. Yield of fluorescence from indocyanine green in plasma and flowing blood. Annals of biomedical engineering. 1995;23:475-81.
[73] Desmettre T, Devoisselle J, Mordon S. Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Survey of ophthalmology. 2000;45:15-27.
[74] 賴允涵. 製備包覆靛氰綠之聚乳酸甘醇酸標靶奈米粒子用於乳癌光熱暨光動治療之研究. 桃園縣: 國立中央大學; 2015.
[75] Saxena V, Sadoqi M, Shao J. Degradation kinetics of indocyanine green in aqueous solution. Journal of pharmaceutical sciences. 2003;92:2090-7.
[76] Engel E, Schraml Rd, Maisch T, Kobuch K, König B, Szeimies R-M, et al. Light-induced decomposition of indocyanine green. Investigative ophthalmology & visual science. 2008;49:1777-83.
[77] 宋信文, 陳松青. 生醫材料簡介. 生物產業技術概論, 第二章. 2003:33-58.
[78] 李玉寶, 顧寧, 魏于全. 奈米生醫材料. 初版, 台北, 五南出版股份有限公司. 2006:162-84.
[79] Whittlesey KJ, Shea LD. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface. Experimental Neurology. 2004;190:1-16.
[80] Roderick HL, Campbell AK, Llewellyn DH. Nuclear localisation of calreticulin in vivo is enhanced by its interaction with glucocorticoid receptors. FEBS letters. 1997;405:181-5.
[81] Kim E-M, Jeong H-J, Park I-K, Cho CS, Bom H-S, Kim C-G. Monitoring the effect of PEGylation on polyethylenimine in vivo using nuclear imaging technique.Nuclear medicine and biology. 2004;31:781-4.
[82] Ghosh S. Recent research and development in synthetic polymer-based drug delivery systems.Journal of Chemical Research. 2004;2004:241-6.
[83] Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews. 2012;64:72-82.
[84] Leong K, D′Amore P, Marletta M, Langer R. Bioerodible polyanhydrides as drug‐carrier matrices. II. Biocompatibility and chemical reactivity. Journal of biomedical materials research. 1986;20:51-64.
[85] Stolnik S, Illum L, Davis S. Long circulating microparticulate drug carriers. Advanced Drug Delivery Reviews. 2012;64:290-301.
[86] Fuchs S, Kapp T, Otto H, Schöneberg T, Franke P, Gust R, et al. A Surface‐Modified Dendrimer Set for Potential Application as Drug Delivery Vehicles: Synthesis, In Vitro Toxicity, and Intracellular Localization.Chemistry–A European Journal. 2004;10:1167-92.
[87] 馬光輝, 蘇志國. 新型高分子材料. 曉園出版社; 2006.
[88] Jeong J-M, Chung Y-C, Hwang J-H. Enhanced adjuvantic property of polymerized liposome as compared to a phospholipid liposome.Journal of biotechnology. 2002;94:255-63.
[89] Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011;6:877-95.
[90] Langer JATR. Erosion kinetics of hydrolytically degradable polymers. 1993:Vol. 90, pp. 552-6,.
[91] Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier.Polymers. 2011;3:1377-97.
[92] Harris Z, Zalipsky S. Poly(ethylene Glycol): American; 1997.
[93] Cagdas FM, Ertugral N, Bucak S, Atay NZ. Effect of preparation method and cholesterol on drug encapsulation studies by phospholipid liposomes.Pharmaceutical development and technology. 2011;16:408-14.
[94] 周志謂. 神奇的奈米鍊丹術. 科學發展. 2008;431:16-22.
[95] Bae KH, Mok H, Park TG. Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death. Biomaterials. 2008;29:3376-83.
[96] Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. The Chemical Record. 2010;10:366-76.
[97] Otsuka H, Nagasaki Y, Kataoka K. Self-assembly of poly (ethylene glycol)-based block copolymers for biomedical applications. Current Opinion in Colloid & Interface Science. 2001;6:3-10.
[98] Kim T-i, Ou M, Lee M, Kim SW. Arginine-grafted bioreducible poly (disulfide amine) for gene delivery systems. Biomaterials. 2009;30:658-64.
[99] Silverstein SC, Steinman RM, Cohn ZA. Endocytosis.Annual review of biochemistry. 1977;46:669-722.
[100] BiologyExams4U.com.Membrane transport for Macromolecules. 2016.
[101] Gillies ER, Fréchet JM.pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjugate chemistry. 2005;16:361-8.
[102] Omelyanenko V, Kopečková P, Gentry C, Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.Journal of Controlled Release. 1998;53:25-37.
[103] Duncan R.The dawning era of polymer therapeutics. Nature reviews Drug discovery. 2003;2:347-60.
[104] 林宜美. 幾丁質摻合聚乳酸酯微粒於藥物釋放系統之研究; Chitin/PLGA blend microspheres as a biodegradable drug delivery system: Phase separation, degradation and release behavior. 2002.
[105] 魏宗平. PLGA 微球包覆 Rapamycin 與蠶絲蛋白/明膠形成複合薄膜之藥物釋放探討. 2012.
[106] 賴秀英. 缽式包覆阿斯匹靈藥物與控制釋放之研究. 臺北科技大學化學工程研究所學位論文. 2010:1-115.
[107] Ta HT, Dass CR, Dunstan DE.Injectable chitosan hydrogels for localised cancer therapy.Journal of Controlled Release. 2008;126:205-16.
[108] Seyednejad H, Ghassemi AH, van Nostrum CF, Vermonden T, Hennink WE.Functional aliphatic polyesters for biomedical and pharmaceutical applications.Journal of Controlled Release. 2011;152:168-76.
[109] Karamanev D, Nikolov L. Influence of some physicochemical parameters on bacterial activity of biofilm: ferrous iron oxidation by Thiobacillus ferrooxidans. Biotechnology and bioengineering. 1988;31:295-9.
[110] 周幸儀. 動態光散射儀之建構與應用. 台南市: 南台科技大學; 2013.
[111] 林怡秀. Chenodeoxycholic acid微胞形成之研究. 花蓮縣: 國立東華大學; 2011.
[112] Tavano L, Pinazo A, Abo-Riya M, Infante M, Manresa M, Muzzalupo R, et al. Cationic vesicles based on biocompatible diacyl glycerol-arginine surfactants: Physicochemical properties, antimicrobial activity, encapsulation efficiency and drug release. Colloids and Surfaces B: Biointerfaces. 2014;120:160-7.
[113] Hallett F, Watton J, Krygsman P. Vesicle sizing: number distributions by dynamic light scattering. Biophysical journal. 1991;59:357.
[114] Lakowicz JR. Principles of fluorescence spectroscopy: Springer Science & Business Media; 2013.
[115] 陳虹瑋. 癌症標靶材料作用於細胞與分子機制之探討:1.多光子趨動標靶化奈米鑽石誘發癌細胞死亡之機制;2.anti-CEACAM6與anti-HER-2單一抗原結合功能區抗體於乳癌標靶治療之研究。. 新竹市: 國立交通大學; 2011.
[116] Morgan HP, McNae IW, Nowicki MW, Zhong W, Michels PA, Auld DS, et al. The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site. Journal of Biological Chemistry. 2011;286:31232-40.
[117] Braut-Boucher F, Pichon J, Rat P, Adolphe M, Aubery M, Font J. A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes.Journal of immunological methods. 1995;178:41-51.
[118] Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry.Nature protocols. 2006;1:1458-61.
[119] Lecoeur H. Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases. Experimental cell research. 2002;277:1-14.
[120] Tuyen Dao TP, Nguyen TH, To VV, Ho TH, Nguyen TA, Dang MC. A new formulation of curcumin using poly (lactic-co-glycolic acid)—polyethylene glycol diblock copolymer as carrier material. Advances in Natural Sciences: Nanoscience and Nanotechnology. 2014;5:035013.
[121] Silverstein RM, Webster FX, Kiemle DJ, Bryce DL. Spectrometric identification of organic compounds: John Wiley & Sons; 2014.
[122] Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28:869-76.
[123] Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103:6315-20.
[124] Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. Journal of Controlled Release. 2009;133:11-7.
[125] Wang S, Mamedova N, Kotov NA, Chen W, Studer J. Antigen/Antibody Immunocomplex from CdTe Nanoparticle Bioconjugates. Nano Letters. 2002;2:817-22.
[126] Jiang S, Zhang Y, Lim KM, Sim EK, Ye L. NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA. Nanotechnology. 2009;20:155101.
[127] Yang J, Lee C-H, Park J, Seo S, Lim E-K, Song YJ, et al. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. Journal of Materials Chemistry. 2007;17:2695.
[128] Mo Y, Lim L-Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. Journal of Controlled Release. 2005;107:30-42.
[129] Barua S, Yoo J-W, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proceedings of the National Academy of Sciences. 2013;110:3270-5.
[130] Zheng M, Yue C, Ma Y, Gong P, Zhao P, Zheng C, et al. Single-step assembly of DOX/ICG loaded lipid–polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS NANO. 2013;7:2056-67.
[131] Lim YT, Noh YW, Han JH, Cai QY, Yoon KH, Chung BH. Biocompatible Polymer‐Nanoparticle‐Based Bimodal Imaging Contrast Agents for the Labeling and Tracking of Dendritic Cells. Small. 2008;4:1640-5.
[132] Saxena V, Sadoqi M, Shao J. Enhanced photo-stability, thermal-stability and aqueous-stability of indocyanine green in polymeric nanoparticulate systems. Journal of Photochemistry and Photobiology B: Biology. 2004;74:29-38.
[133] Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and original investigations: Elsevier; 2008. p. 57-64.
[134] Zolnik BS, Leary PE, Burgess DJ. Elevated temperature accelerated release testing of PLGA microspheres. Journal of Controlled Release. 2006;112:293-300.
[135] Hakkarainen M, Albertsson A-C, Karlsson S. Weight losses and molecular weight changes correlated with the evolution of hydroxyacids in simulated in vivo degradation of homo-and copolymers of PLA and PGA. Polymer Degradation and Stability. 1996;52:283-91.
[136] Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochemical and biophysical research communications. 2007;353:26-32. |